This page shows the latest Age-related macular degeneration news and features for those working in and with pharma, biotech and healthcare.
older and cheaper alternative drug to treat wet age-related macular degeneration (AMD).
Roche has announced the approval of Vabysmo (faricimab) by the European Commission (EC) for the treatment of neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema
Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.
Roche has announced two-year data reinforcing the long-term efficacy, safety and durability of Vabysmo (faricimab) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of ... Age-related macular degeneration (AMD) is
GA is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.
More from news
Approximately 5 fully matching, plus 124 partially matching documents found.
for advanced dry Age-related Macular Degeneration (AMD). ... She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry
treatments for age-related macular degeneration (AMD).
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD). ... Despite the uncertainty and challenges in our environment, particularly related to Brexit, we need
company. Avalanche's preclinical and research stage gene therapy programmes are focused on a range of ophthalmic diseases, such as wet age-related macular degeneration, utilising adeno-associated virus (AAV) vectors. ... Onxeo is paying around $1.85m
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
She said: “I am excited to be joining Gyroscope at the company’s founding stage to advance new genetically-defined therapies for the treatment of debilitating eye diseases such as ... related macular degeneration.
While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of ... Because of my mother, I was on the other side
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...